[Current status of thrombolysis. The need for coadjuvant antithrombotic therapy]. / Estado actual de la trombolisis. Necesidad de la terapéutica antitrombótica coadyuvante.
Rev Clin Esp
; 193(2): 88-92, 1993 Jun.
Article
em Es
| MEDLINE
| ID: mdl-8341821
ABSTRACT
Thrombolytic therapy yields a 80% repermeabilitation in the acute myocardium infarct if applied soon. In other thrombotic sites such as deep venous thrombosis, pulmonary thromboembolism and peripheral arterial thrombosis, with no large cooperative randomized clinical trials, its usefulness is clear, tough selectively. The high rethrombosis frequency is the major drawback of this therapy. The concomitant use of an anti-thrombotic and/or anti-aggregant agent, even tough the possible higher risks of hemorrhages, seems a key element to improve the results obtained with thrombolysis.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Terapia Trombolítica
/
Fibrinolíticos
Idioma:
Es
Ano de publicação:
1993
Tipo de documento:
Article